Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gatifloxacin
Drug ID BADD_D01006
Description Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan.
Indications and Usage For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes
Marketing Status approved; investigational
ATC Code J01MA16; S01AE06
DrugBank ID DB01044
KEGG ID D00589; D08011
MeSH ID D000077734
PubChem ID 5379
TTD Drug ID D03CQE
NDC Product Code 53476-1155; 50383-189; 68180-435; 60758-615; 61314-672; 0023-3615
UNII L4618BD7KJ
Synonyms Gatifloxacin | 1-cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid | Gatifloxacine | Tequin | AM 1155 | AM-1155 | CG 5501 | BMS-206584 | BMS 206584 | BMS206584 | Zymar
Chemical Information
Molecular Formula C19H22FN3O4
CAS Registry Number 112811-59-3
SMILES CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Ageusia07.14.03.003; 17.02.07.001---
Agitation17.02.05.012; 19.06.02.001--
Alanine aminotransferase increased13.03.04.005--
Alcohol intolerance14.02.01.001--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anxiety19.06.02.002--
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.001---
Asthma10.01.03.010; 22.03.01.002---
Ataxia08.01.02.004; 17.02.02.001--
Back pain15.03.04.005--
Blepharitis allergic06.04.04.009; 10.01.03.034; 23.03.04.030---
Body temperature increased13.15.01.001---
Bone pain15.02.01.001--
Bradycardia02.03.02.002---
Breast pain21.05.05.003--
Breath odour07.01.06.002---
Bronchospasm10.01.03.012; 22.03.01.004--
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Cheilitis07.05.01.001; 23.03.03.025--
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Chills08.01.09.001; 15.05.03.016--
Colitis07.08.01.001--
Confusional state17.02.03.005; 19.13.01.001--
Conjunctival cyst06.12.01.002; 16.34.01.002---
Conjunctival haemorrhage06.07.01.001; 24.07.05.001---
Conjunctival irritation06.04.01.007---
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene